Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Crenolanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 6/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | APRT | P07741 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crenolanib SCHEMBL29350134 | 1.00 | FLT3 (1.00) | FLT3IRAK4GAKRIPK2ULK1 | |
| Crenolanib SCHEMBL2730601 | 1.00 | FLT3 (1.00) | FLT3IRAK4GAKRIPK2ULK1 | |
| Crenolanib SCHEMBL30002138 | 1.00 | FLT3 (1.00) | FLT3IRAK4GAKRIPK2ULK1 | |
| SCHEMBL22567082 | 0.93 | IRAK4 (0.86) | FLT3IRAK4GAKRIPK2ULK1 | |
| Crenolanib SCHEMBL29361948 | 0.92 | FLT3 (0.85) | FLT3IRAK4GAKRIPK2ULK1 | |
| Crenolanib SCHEMBL4681285 | 0.92 | FLT3 (0.85) | FLT3IRAK4GAKRIPK2ULK1 | |
| Crenolanib SCHEMBL29352554 | 0.92 | FLT3 (0.85) | FLT3IRAK4GAKRIPK2ULK1 | |
| SCHEMBL5662568 | 0.92 | IRAK4 (0.85) | FLT3IRAK4GAKRIPK2ULK1 | |
| SCHEMBL30775111 | 0.92 | FLT3 (0.85) | FLT3IRAK4GAKRIPK2ULK1 | |
| SCHEMBL27030604 | 0.92 | FLT3 (0.85) | FLT3IRAK4GAKRIPK2ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2342 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743086-A2 | TREATING MYELOID DISORDERS | Mayo Foundation for Medical Education and Research (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4744729-A2 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | Deciphera Pharmaceuticals, LLC (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260115166-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PHOTORECEPTOR ROD DEGENERATIONS AND GENERATION OF PHOTORECEPTORS | PURDUE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4731220-A2 | METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | Dana Farber Cancer Institute, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| EP-4722388-A1 | PREDICTION OF AN OUTCOME OF A SUBJECT SUFFERING FROM ACUTE MYOLOID LEUKEMIA | Koninklijke Philips N.V. (NL) | 2026-04-08 | — | — | EP | claimed |
| EP-4719387-A2 | COMPLEMENT ANTIBODY-DRUG CONJUGATES | ADS Therapeutics LLC (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4701664-A1 | METHODS OF TREATING TKI-RESISTANT AND SDH-DEFICIENT GIST | Guangzhou Healthquest Pharma Co., Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | claimed |
| US-20260027119-A1 | INHIBITORS OF CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II AND THEIR USES | UNIV JOHNS HOPKINS (US) | 2026-01-29 | — | — | US | claimed |
| US-20220133710-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS, INC. | 2022-05-05 | — | — | US | claimed |
| US-20220133730-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS LLC (US) | 2022-05-05 | — | — | US | claimed |
| CN-108024544-B | Delivery methods and compositions for nuclease-mediated genome engineering | 桑格摩生物治疗股份有限公司 | 2022-04-29 | — | — | CN | claimed |
| EP-3373932-B1 | CRYSTALLINE FORM OF A SUBSTITUTED QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-03-30 | — | — | EP | claimed |
| US-20220079933-A1 | CRENOLANIB FOR TREATING TRK KINASE ASSOCIATED PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS, INC. | 2022-03-17 | — | — | US | claimed |
| US-20220079934-A1 | CRENOLANIB FOR TREATING PAIN | AROG PHARMACEUTICALS, INC. | 2022-03-17 | — | — | US | claimed |
| EP-3962559-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2022-03-09 | — | — | EP | claimed |
| US-20220047577-A1 | CRENOLANIB FOR TREATING PDGFR ALPHA MUTATED PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS, INC. | 2022-02-17 | — | — | US | claimed |
| US-20220047574-A1 | CRENOLANIB FOR TREATING PDGFR ALPHA MUTATED PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS, INC. | 2022-02-17 | — | — | US | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |